Analysis of the Application Effect of Albumin-bound Paclitaxel Combined with Cisplatin in the Initial Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma
Objective To explore the application effect of albumin bound paclitaxel combined with cisplatin in the ini-tial treatment of locally advanced esophageal squamous cell carcinoma.Methods The clinical data of 62 patients with locally advanced esophageal squamous cell carcinoma admitted to the Oncology Department of Funing County People's Hospital from January 2021 to March 2023 were retrospectively selected.According to different treatment options,they were divided into reference group and treatment group,31 cases each.The reference group received paclitaxel combined with cisplatin chemotherapy,and the treatment group received albumin-bound paclitaxel combined with cis-platin chemotherapy.The efficacy,tumor markers and incidence of adverse effects were compared between patients in two groups.Results The effective rate of the treatment group(83.67%)was higher than that of the reference group(61.29%),and the difference was statistically significant(χ2=3.971,P=0.046).Before chemotherapy,there was no sig-nificant difference in the level of tumor markers between the two groups(P＞0.05).After chemotherapy,the levels of tu-mor markers such as carcinoembryonic antigen,carbohydrate antigen 19-9 and squamous cell carcinoma antigen in the treatment group were lower than those in the reference group,and the differences were statistically significant(t=5.314,3.880,14.449,all P＜0.001).The incidence of myalgia(25.81%)and bone marrow suppression(32.26%)in the treatment group was significantly lower than that in the control group(51.61%,61.29%),the differences were statisti-cally significant(χ2=4.351,5.247,both P＜0.05).Conclusion The combination of albumin bound paclitaxel and cispla-tin has significant efficacy and safety in the initial treatment of locally advanced esophageal squamous cell carcinoma,and can reduce the level of tumor markers.Its application value is significant.
NETL
NSTL
万方数据
